These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20521352)

  • 41. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule.
    Groen HJ; Fokkema E; Biesma B; Kwa B; van Putten JW; Postmus PE; Smit EF
    J Clin Oncol; 1999 Mar; 17(3):927-32. PubMed ID: 10071286
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.
    Socinski MA; Weissman C; Hart LL; Beck JT; Choksi JK; Hanson JP; Prager D; Monberg MJ; Ye Z; Obasaju CK
    J Clin Oncol; 2006 Oct; 24(30):4840-7. PubMed ID: 17050869
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study.
    Mavroudis D; Pavlakou G; Blazoyiannakis G; Veslemes M; Apostolopoulou F; Kouroussis Ch; Kakolyris S; Agelaki S; Androulakis N; Vardakis N; Magkanas E; Samonis G; Georgoulias V
    Lung Cancer; 2003 Jan; 39(1):71-6. PubMed ID: 12499097
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer.
    Zhou ZT; Zhou FX; Wei Q; Zou LY; Qin BF; Peng XS
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1027-32. PubMed ID: 21327933
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma.
    Tas F; Derin D; Guney N; Camlica H; Aydiner A; Topuz E
    Lung Cancer; 2007 Jul; 57(1):79-83. PubMed ID: 17383768
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie study.
    Thomas P; Castelnau O; Paillotin D; Léna H; Robinet G; Muir JF; Delaval P; Gouva S; Balmes P; Blanchon F; Perdu D; Poirier R; Pommier De Santi P; Penot-Ragon C; Kleisbauer JP
    J Clin Oncol; 2001 Mar; 19(5):1320-5. PubMed ID: 11230474
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer.
    Hobdy EM; Kraut E; Masters G; Blum K; McKeon A; Byrd B; Davies M; Beaulieu N; Murren JR
    Cancer Biol Ther; 2004 Jan; 3(1):89-93. PubMed ID: 14726661
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.
    Quoix E; Breton JL; Gervais R; Wilson J; Schramel F; Cardenal F; Ross G; Preston A; Lymboura M; Mattson K
    Lung Cancer; 2005 Aug; 49(2):253-61. PubMed ID: 16022920
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer.
    Vecchione F; Fruscio R; Dell'Anna T; Garbi A; Garcia Parra R; Corso S; Lissoni AA
    Int J Gynecol Cancer; 2007; 17(2):367-72. PubMed ID: 17362314
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study.
    Frasci G; Nicolella G; Comella P; Carreca I; DeCataldis G; Muci D; Brunetti C; Natale M; Piantedosi F; Russo A; Palmeri S; Comella G; Panza N
    Br J Cancer; 2001 May; 84(9):1166-71. PubMed ID: 11336465
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
    Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
    J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer.
    Molina JR; Jett JR; Foster N; Lair BS; Carroll TJ; Tazelaar HD; Hillman S; Mailliard JA; Bernath AM; Nikcevich D
    Am J Clin Oncol; 2006 Jun; 29(3):246-51. PubMed ID: 16755177
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer.
    Inoue A; Yamazaki K; Maemondo M; Suzuki T; Kimura Y; Kanbe M; Isobe H; Nishimura M; Saijo Y; Nukiwa T
    J Thorac Oncol; 2006 Jul; 1(6):551-5. PubMed ID: 17409916
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II study of oral topotecan in advanced non-small cell lung cancer.
    White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
    Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
    Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
    Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase II trial of vinflunine in relapsed small cell lung cancer.
    Spigel DR; Hainsworth JD; Lane CM; Clark B; Burris HA; Greco FA
    J Thorac Oncol; 2010 Jun; 5(6):874-8. PubMed ID: 20521355
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
    Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
    Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
    Eckardt JR; von Pawel J; Pujol JL; Papai Z; Quoix E; Ardizzoni A; Poulin R; Preston AJ; Dane G; Ross G
    J Clin Oncol; 2007 May; 25(15):2086-92. PubMed ID: 17513814
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
    Ikeda T; Fukuda M; Nakamura Y; Kinoshita A; Senju H; Nakano H; Kitazaki T; Ogawara D; Taniguchi H; Motoshima K; Yamaguchi H; Nakatomi K; Shimada M; Nagashima S; Tsukamoto K; Kohno S;
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):497-502. PubMed ID: 25034978
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.
    Paik PK; Rudin CM; Pietanza MC; Brown A; Rizvi NA; Takebe N; Travis W; James L; Ginsberg MS; Juergens R; Markus S; Tyson L; Subzwari S; Kris MG; Krug LM
    Lung Cancer; 2011 Dec; 74(3):481-5. PubMed ID: 21620511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.